ABSTRACT
Introduction
Lung cancer is the leading cause of cancer death in developed countries across the world. 1 Despite the steady decline in lung cancer mortality rates over the past two decades, lung cancer accounts for approximately 21% of all cancer deaths in England and 26% in the United States. 2, 3 In addition to comprehensive tobacco control programs 4 that have led to a dramatic decrease in the prevalence of cigarette smoking, the evolving clinical landscape of lung cancer care and outcomes is being shaped by newer approaches to early detection and treatment. 5, 6 As these techniques diffuse into clinical practice, understanding how care differs between health systems represents an opportunity for improvement.
In comparisons across developed countries such as England and the United States, substantial variation exists in lung cancer incidence and mortality. 7 Agestandardized lung cancer mortality rates were higher in England than in the United States in 2014 for both men (72.9 versus 55.9 per 100,000 population) and women (48.4 versus 36.3 per 100,000 population). 2, 8 Several population-based research studies, including EUROCARE, CONCORD, and the International Cancer Benchmarking Partnership, have revealed substantive international differences in cancer outcomes, with patients in England tending to experience lower survival. 7, 9, 10 Efforts to estimate and compare care and outcomes across health systems have been disjointed, however, owing to challenges in collecting comparable data that are population based and contain sufficient clinical detail. For instance, in a comparison of EURO-CARE cancer registries from 17 European countries with the data from the Surveillance and Epidemiology End Results (SEER) Program in the United States, survival for most major cancers was lower in Europe. However, this study lacked information on stage and primary treatment, with many countries reporting data on only a subset of the population. 11 The CONCORD-2 global cancer surveillance study reported wide differences in 5-year age-standardized net lung cancer survival rates (9.6% in England versus 18.7% in the United States for 2005-2009), 12 a difference that was thought to be driven by the intensity of diagnostic activity, tumor staging at diagnosis, and treatment but was ultimately concluded to be due to the face that the comparability of data on cancer stage and treatment remains poor. 7, [13] [14] [15] [16] Hence, more detailed population-based comparisons between the health systems in the United States and Europe are needed.
The growing costs of cancer care, coupled with the international divide in outcomes, raises questions regarding best practices for and the value of investment in health care resources. The higher survival rates in the United States likely reflect earlier diagnosis, more aggressive treatment, and utilization of new technologies. 17 However, a better understanding of the differences between health systems is required to maximize the return on investment in cancer care. This is particularly important in older patients, as the median age at diagnosis for NSCLC is approximately 70 years. 18, 19 Older patients are frequently excluded from clinical trials, reducing the generalizability of evidence-based medical practice 20 and resulting in greater variation in clinical practice. 21 We performed a collaborative investigation of diagnostic, treatment, and survival patterns in older patients with a diagnosis of NSCLC between England and United States. Specifically, we compared the two health care systems from the standpoints of distribution of stage at diagnosis, use of cancer-directed treatment, and survival. In addition, we aimed to estimate the degree to which stage at diagnosis and receipt of cancer treatment mitigated potential differences in survival between countries.
Materials and Methods

Study Design and Data Sources
Data for this retrospective cohort study were obtained from population-based cancer surveillance registries and administrative databases in England and the United States. In England, patient-level data were identified in the combined National Cancer Analysis System (CAS), Public Health England's National Cancer Registration and Analysis Service (NCRAS), the National Lung Cancer Audit (LUCADA) database, and the Hospital Episode Statistics 22 database. The Office for Data Release in Public Health England extracted lung cancer records from the national CAS 2013 database and linked them to the LUCADA 2012 23 and Hospital Episode Statistics data sets by National Health Service number. Patient-level data from the United States were provided by the linked SEER-Medicare database maintained by the National Cancer Institute (NCI), which is responsible for linkage between the SEER database and administrative claims for Medicare-eligible persons residing in the areas covered by the 17 SEER regional cancer registries. 24 Details on data sources are available in the Supplementary Methods.
Population
We included all incident cases of invasive NSCLC diagnosed in 2008-2011 in the SEER-Medicare database and in 2009-2012 in the LUCADA and NCRAS databases for patients age 66 years or older. We excluded patients whose tumor registration was made from a death certificate or on the basis of autopsy only, as well as patients with a pathologically confirmed diagnosis of SCLC.
Data Elements and Measures
Patient-level information included sociodemographic characteristics (year of diagnosis, age, and sex) as well as clinicopathological characteristics, including diagnostic confirmation, stage, and histologic subtype. We calculated the proportion of patients with a pathologically confirmed diagnosis of NSCLC, combining the basis of diagnosis variables in the CAS and LUCADA databases for England and using the diagnostic confirmation variable in the SEER database for the United States.
The Treatment characteristics included first-line surgery, receipt of chemotherapy or radiotherapy, and any active treatment from 1 month before through 6 months after initial diagnosis (see the Supplementary Methods). For comparisons of treatment modalities other than surgery (radiotherapy or chemotherapy and any active treatment) across the two health care systems, the U.S. sample was restricted to patients with continuous feefor-service (FFS) Medicare coverage from 1 year before through 6 months after diagnosis to capture initial treatment. We restricted the U.S. sample to patients with continuous FFS coverage because the SEER data alone do not reliably capture chemotherapy or radiotherapy. 24, 25 Date of diagnosis is defined in the English register according to European rules 26 and for the United States according to SEER-Medicare standards. 27 Survival time was calculated as the total number of months from the date of diagnosis to date of death or the censoring date of December 12, 2013 .
We calculated the number of excess deaths from lung cancer that were due to differences in stage distribution at diagnosis and stage-specific survival in England versus in the United States by using observed stage distribution and the 2-year estimated stage-specific relative survival (RS). We compared the observed number of patients alive within 2 years of diagnosis with the expected number if either the stage distribution or the 2-year stage-specific RS in England mirrored the observed distribution in the United States.
Institutional review board approval for the study was obtained both in England and in the United States.
Statistical Analysis
In accordance with study protocols, the two health system databases were not combined in any analyses, and access to the data was limited to the investigators at their respective study sites. Rather than creating a joint patient-level database, summary estimates from each health system were reported and compared. Overall differences in patient and treatment-related characteristics between the two countries were assessed by chisquare and Mantel-Haenszel tests. Differences between categories were presented with their binomial 99% confidence intervals (CIs). We calculated agestandardized estimates for the proportion of patients receiving different treatment modalities by stage by using the U.S. 2000 standard population. 28 For each country, we estimated overall survival (OS) by using the Kaplan-Meier method. Patients with a survival time of zero were included. 29 We also estimated 1-and 2-year RS rates, which were measured as the ratio of observed to expected survival by using life table methods and the Ederer II method to calculate expected survival. 30 We used country-specific life tables (for the years 2008-2013 for the United States and the years 2009-2013 for England), which included survival probability for each year by sex and single year of age from 66 to 99 years. As the English life tables were calculated by the Office for National Statistics with a period of 3 consecutive years, 31 we used the Office for National Statistics estimate for the central year of the period (e.g., for 2009 we used the 2008-2010 period estimate). We also estimated RS in subgroups according to demographic characteristics, stage, and treatment. Calculations for the number of excess deaths were produced by using 2-year RS estimates and the lower and upper limits of the 95% confidence intervals to obtain a minimum and a maximum for the predictions.
All statistical analyses were performed with SAS software (version 9.4, SAS Institute Inc., Cary, NC).
Figures were produced with R software (version 3.3.0, R Foundation for Statistical Computing, Vienna, Austria).
Results
We identified a total of 91,322 patients in the English database and 101,600 patients in the U.S. database ( Supplementary Fig. 1 ). After application of the exclusion criteria, the final samples consisted of 86,978 patients for England and 84,415 patients for the United States.
Seventy-five percent (n ¼ 65,496) of the final English sample linked to a LUCADA record, and 64%. (n ¼ 54,318) of the final U.S. patient sample had continuous FFS Medicare coverage from 1 year before through 6 months after diagnosis.
We found slight differences in age and sex distribution between the two countries ( Table 1 ). The proportion of patients without pathological confirmation was higher in England (37%) than in the United States (15%) (a 22.2% difference [99% CI: 22.8%-21.7%]). In England, the proportion of patients without pathological all treatment modalities were observed for patients with stage II disease (see Table 2 ). Compared with the United States, England had an approximately 7% smaller absolute difference in the proportion of patients receiving an operation in all age classes (from a 6.8% difference in the 66-70 years age group to a 7.7% difference in the 76-80 years age group) ( (Fig. 1) . When the confidence intervals for the first and last year of diagnosis were compared, an improvement in 1-year RS was observed for all age and sex subgroups in England, but only for women age 66 to 80 years in the United States (Supplementary Table 2 ).
The disparity in survival rates between the two countries varied according to stage at diagnosis. For instance, the 1-and 2-year RS rates for stage I disease were similar between England and the United States for patients with pathological confirmation and for patients receiving treatment (see Table 4 ). Although the 1-year RS rate for patients with stage II disease who underwent an operation was similar between England and the United States (83.6% [95% CI: 81.9%-85.2%] versus 84.0% [95% CI: 82.1%-85.7%]), survival was significantly lower among patients in England with stage IIIA and IIIB or IV disease, regardless of the type of treatment received, as shown by the nonoverlapping confidence intervals (see Table 4 and Supplementary Table 1 ). Although the RS rate was higher in the United States, when the confidence intervals for the first and last year of diagnosis were compared, the 2-year stage-specific RS rate in England increased from 2009 to 2011 among stage I patients undergoing any active treatment and overall, whereas estimates remained stable for the United States in the same period (see Supplementary Table 3) .
In a random sample of 1000 patients with pathological confirmation from each country, a total of 246 patients from England and 344 from the United States were (Fig. 2) . The latter would be due almost entirely to the larger proportion of patients with a diagnosis of stage IIIA or IV disease surviving to 2 years (see Table 4 ).
Discussion
In a population-based sample of approximately 170,000 older patients with cancer diagnosed as NSCLC, we identified substantive differences between England and the United States regarding diagnostic approach, stage at diagnosis, treatment patterns, and survival. Across the study period, the rate of pathological confirmation and the proportion of patients with missing stage at diagnosis were key process of care indicators in our study. We found lower rates of pathological confirmation in England versus in the United States, particularly among the oldest patients, with a concomitant higher rate of patients with no recorded stage at diagnosis in England. These findings may reflect differences between the two countries in terms of the level of awareness of and approach to the diagnosis and treatment of older, and particularly very old, patients, 23 and these differences should be taken into consideration when interpreting comparisons limited to patients for whom there was pathological confirmation.
We observed a lower rate of diagnosis of stage I disease in England than in the United States. Policies targeting early detection and diagnosis are imperative, as 44 deaths for every 1000 patients could be avoided at 32, 33 has demonstrated that for approximately 40% of patients lung with cancer, diagnosis is first made as part of an emergency hospital admission. The rate of emergency presentation is higher in older patients, and the 1-year survival rate is significantly lower in those whose disease is diagnosed at emergency presentation across all ages than in those whose disease is diagnosed by other routes. 33 Stage distribution is a particularly important public health concern in lung cancer, given the recent evidence that computed tomography-based screening can decrease lung cancer mortality. 34, 35 The dissemination of screening into clinical practice has occurred within the last 5 years in some countries, including in the United States. [34] [35] [36] Therefore, it is possible that differential screening practices across countries could exacerbate existing differences in early-stage diagnosis in the near future.
Treatment rates also differed: we found that the difference in rate of receipt of chemotherapy or radiotherapy, which was lower in England than in the United States, widened in patients age 75 or older. Among very old patients, access to treatment is generally reduced not only because of comorbidities and social difficulties 37, 38 but also because of refusal of treatment despite evidence of a survival benefit. 39, 40 The circumstances surrounding perceptions of and preferences for cancer treatment at the end of life among the oldest patients may vary across countries.
Intensity of treatment and management of care are fundamental across all stages of disease. If England were to have the same stage-specific 2-year RS rate as the United States, a total of 62 deaths for every 1000 patients could be avoided, primarily for patients with stage IIIA, IIIB, or IV disease. The lower 2-year RS rates found in England for more advanced stages can probably be attributed to lower treatment rates, both in terms of surgery for stage IIIA and IIIB disease and in terms of medical oncologic treatment.
Differences in population demographics are unlikely to explain the results, as relative-survival rates were used to compare survival outcomes. In addition, the estimated prevalence of smoking by sex in the 1980s was similar between the two countries (35% in the United Kingdom in 1986 versus 34% in the United States in 1985 for men and 31% versus 28% for women), 41, 42 leading to similar incidence rates in both sexes. One limitation of this study is that we did not perform pooled analyses of the data from England and the United States because of the different protection laws. Care was taken, however, to define variables and perform analogous statistical analysis with use of identical procedures and software. Second, the available databases did not include comparable information on specific chemotherapy agents, type of radiotherapy, or curative versus palliative intent of treatment for the analyzed years, potentially confounding comparisons for this group of patients. Similarly, we did not have access to information on performance status or comorbidities, both of which may have differed between England and the United States, and as indicators of general fitness of the populations, both could be factors explaining, at least in part, the differences in treatment rates.
Overall, we have demonstrated the ability to compare two large health care systems across process and outcome measures for NSCLC in England and the United States by utilizing databases containing data from cancer registries that are linked to clinical and administrative data sets. Our results underscore the importance of performing like-with-like comparisons between patient groups, which requires data relating to pathological confirmation of the tumor, staging data at diagnosis, and receipt of treatment. We found a lower proportion of older patients with advanced-stage lung cancer who were receiving care and lower RS rates in patients whose NSCLC was diagnosed in England versus in the United States, even when comparing groups receiving the same type of treatment. These important findings demand future research to disentangle potential causes by incorporating comorbidity and socioeconomic variables into comparisons and extending comparisons to other cancer sites and countries so as to better understand the determinants of differences in care and outcomes of patients with cancer across health systems.
